Putting The Pieces Together Again: GSK Creates End-To-End Business Units
At the forefront of radical R&D reorganization, GlaxoSmithKline continues to evolve its model, characterized to date by the breaking up of R&D into small, biotech-like drug performance units (DPUs). These units are about to undergo the latest round of change: closer integration with the downstream medicines development centers in their respective therapeutic areas. The move makes sense given industry's growing recognition of the need for payor and regulator requirements to inform even early-stage discovery and development.
You may also be interested in...
GSK's various thwarted efforts to boost productivity through R&D revamps begs the question whether big pharma should be trying to do in-house discovery and early development at all.
The president of GlaxoSmithKline Oncology talked with “The Pink Sheet” about precision medicine, regulatory climate change, the need to provide value for payers and the company’s commitment to double cancer survival globally over the next 10 years.
During a nearly two-hour R&D seminar, executives at GlaxoSmithKline PLC described the company's evolving strategy, detailing the organization's goals, capital allocation, and productivity performance, and providing a glimpse into the ongoing work within six of its 40 biotech-like discovery performance units.